Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
<p>Abstract</p> <p>Background</p> <p>This phase II study was designed to evaluate the activity and safety of a combination of epirubicin, oxaliplatin and docetaxel in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.</p> <p>Methods</p&...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-03-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Online Access: | http://www.jeccr.com/content/28/1/34 |
| _version_ | 1811265734837272576 |
|---|---|
| author | Fattoruso Silvia Sergi Domenico Arena Maria Giacinti Laura Di Lauro Luigi Giannarelli Diana Lopez Massimo |
| author_facet | Fattoruso Silvia Sergi Domenico Arena Maria Giacinti Laura Di Lauro Luigi Giannarelli Diana Lopez Massimo |
| author_sort | Fattoruso Silvia |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>This phase II study was designed to evaluate the activity and safety of a combination of epirubicin, oxaliplatin and docetaxel in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.</p> <p>Methods</p> <p>Forty patients with measurable distant metastases received epirubicin 50 mg/m<sup>2</sup>, docetaxel 60 mg/m<sup>2 </sup>followed by oxaliplatin 100 mg/m<sup>2 </sup>on day 1 of each 21-day cycle. Primary end point was response rates (RR).</p> <p>Results</p> <p>All patients were evaluable. The overall RR was 47.5% (95% confidence interval (CI) 32–63). The disease control was 80%. Median time for response was 6 weeks. Median time to progression was 6.3 months (95% CI 5.4–7.2) and the median overall survival time was 12.1 months (95% CI 10.7–13.5). Grade 3/4 neutropenia occurred in 50% of patients with two episodes of febrile neutropenia (5%). Other non-hematological grade 3 toxicities included sensory neuropathy in two patiens (5%), vomiting and mucositis in two patients (5%) and diarrhea in one patient (2.5%).</p> <p>Conclusion</p> <p>The combination of epirubicin, oxaliplatin and docetaxel was found to be effective and well tolerated in patiens with metastatic gastric or GEJ adenocarcinoma and maybe an appropriate regimen to be used in the neoadjuvant setting and with molecularly targeted agents.</p> |
| first_indexed | 2024-04-12T20:29:14Z |
| format | Article |
| id | doaj.art-6913eddacb434ceebfcc424295acf234 |
| institution | Directory Open Access Journal |
| issn | 1756-9966 |
| language | English |
| last_indexed | 2024-04-12T20:29:14Z |
| publishDate | 2009-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj.art-6913eddacb434ceebfcc424295acf2342022-12-22T03:17:46ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662009-03-012813410.1186/1756-9966-28-34Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinomaFattoruso SilviaSergi DomenicoArena MariaGiacinti LauraDi Lauro LuigiGiannarelli DianaLopez Massimo<p>Abstract</p> <p>Background</p> <p>This phase II study was designed to evaluate the activity and safety of a combination of epirubicin, oxaliplatin and docetaxel in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.</p> <p>Methods</p> <p>Forty patients with measurable distant metastases received epirubicin 50 mg/m<sup>2</sup>, docetaxel 60 mg/m<sup>2 </sup>followed by oxaliplatin 100 mg/m<sup>2 </sup>on day 1 of each 21-day cycle. Primary end point was response rates (RR).</p> <p>Results</p> <p>All patients were evaluable. The overall RR was 47.5% (95% confidence interval (CI) 32–63). The disease control was 80%. Median time for response was 6 weeks. Median time to progression was 6.3 months (95% CI 5.4–7.2) and the median overall survival time was 12.1 months (95% CI 10.7–13.5). Grade 3/4 neutropenia occurred in 50% of patients with two episodes of febrile neutropenia (5%). Other non-hematological grade 3 toxicities included sensory neuropathy in two patiens (5%), vomiting and mucositis in two patients (5%) and diarrhea in one patient (2.5%).</p> <p>Conclusion</p> <p>The combination of epirubicin, oxaliplatin and docetaxel was found to be effective and well tolerated in patiens with metastatic gastric or GEJ adenocarcinoma and maybe an appropriate regimen to be used in the neoadjuvant setting and with molecularly targeted agents.</p>http://www.jeccr.com/content/28/1/34 |
| spellingShingle | Fattoruso Silvia Sergi Domenico Arena Maria Giacinti Laura Di Lauro Luigi Giannarelli Diana Lopez Massimo Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma Journal of Experimental & Clinical Cancer Research |
| title | Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma |
| title_full | Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma |
| title_fullStr | Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma |
| title_full_unstemmed | Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma |
| title_short | Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma |
| title_sort | phase ii study of epirubicin oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma |
| url | http://www.jeccr.com/content/28/1/34 |
| work_keys_str_mv | AT fattorusosilvia phaseiistudyofepirubicinoxaliplatinanddocetaxelcombinationinmetastaticgastricorgastroesophagealjunctionadenocarcinoma AT sergidomenico phaseiistudyofepirubicinoxaliplatinanddocetaxelcombinationinmetastaticgastricorgastroesophagealjunctionadenocarcinoma AT arenamaria phaseiistudyofepirubicinoxaliplatinanddocetaxelcombinationinmetastaticgastricorgastroesophagealjunctionadenocarcinoma AT giacintilaura phaseiistudyofepirubicinoxaliplatinanddocetaxelcombinationinmetastaticgastricorgastroesophagealjunctionadenocarcinoma AT dilauroluigi phaseiistudyofepirubicinoxaliplatinanddocetaxelcombinationinmetastaticgastricorgastroesophagealjunctionadenocarcinoma AT giannarellidiana phaseiistudyofepirubicinoxaliplatinanddocetaxelcombinationinmetastaticgastricorgastroesophagealjunctionadenocarcinoma AT lopezmassimo phaseiistudyofepirubicinoxaliplatinanddocetaxelcombinationinmetastaticgastricorgastroesophagealjunctionadenocarcinoma |